SINGLE
ENZYME
ACTIVITY-BASED
LIQUID
BIOPSY
We are developing “single enzyme activity-based liquid biopsy”
for early detection of diseases and drug development support.
News
-
Award
Cosomil, Inc. Earns JST President’s Award at Awards for Academic Startups 2023
-
Research
Osaka Metropolitan University and Cosomil collaborate to advance detection of hepatobiliary pancreatic cancers
-
Award
Second Place in MedTech Pitch Contest hosted by LINK-J
-
Award
We will exhibit at the Japan Healthcare Venture Summit 2022
Science
We are developing high-precision liquid-based diagnostic technology using "single enzyme activity-based protein profiling (SEAP),"
to evaluate the activity of enzymes in the blood molecule at single protein level.
Services
Our business focuses on 2 main areas: early disease diagnosis and support for drug development.
For example, by utilizing our "single enzyme activity-based protein profiling (SEAP)" technology, pancreatic cancer may be detected in its early stage.
About
We will contribute to future growth of healthcare
by applying fluorescent enzyme substrates and microdevices.
